Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Used as a systemic drug for cardiac resuscitation and locally in topical anesthetic preparations, epidural anesthesia, eye drops (mydriatic), and nasal drops (vasoconstrictor).
At last update no published data on excretion in breast milk were found.
Its rapid metabolism (short Tmax and T½) makes it unlikely an excretion into milk in significant amounts.
It is destroyed in the gastrointestinal tract. The low oral-bioavailability makes its levels into infant's plasma, that would be absorbed from ingested breast milk, be nil or negligible.
Maintained high intravenous doses decrease milk production by interfering with the secretion of prolactin especially the early postpartum-weeks, because when breastfeeding is well established, prolactin levels do not correlate with milk production any longer.
No problems related to lactation have been observed due to epidural anesthesia in which adrenaline is used.